<!DOCTYPE html>
<html>
  <head> 
    <link href='action.png' rel='icon' type='image/png' />
</head>
        
        <div class="wrapper row1" align="center">
                <head> 
                        <title>vaccine development</title> 
                </head> 
                 
                <body> 
                 
                <div style="width: 1400px; height: 130px; background-color: #29adaf">&nbsp; 
                        
                    <h1>Development Of Specialized Cloud Database For Japanese Encephalitis Virus ( JEV-1871 )</h1>
                  </div>
                </header>
              </div>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <title>Japanese Encephalitis Vaccine Candidates</title>
  <style>
    body {
      font-family: Arial, sans-serif;
      margin: 40px;
      background: #f9f9f9;
    }

    h2 {
      text-align: center;
      margin-bottom: 10px;
      color: #333;
    }

    table {
      width: 90%;
      border-collapse: collapse;
      margin: 20px auto;
      box-shadow: 0 0 12px rgba(0, 0, 0, 0.1);
      background-color: white;
    }

    th, td {
      padding: 12px 15px;
      border: 1px solid #ddd;
      text-align: center;
    }

    thead {
      background-color: #007BFF;
      color: white;
    }

    tbody tr:nth-child(even) {
      background-color: #f2f2f2;
    }

    caption {
      caption-side: top;
      font-weight: bold;
      font-size: 1.2em;
      margin: 10px;
    }
  </style>
</head>
<body>

  <!-- Table 1: Licensed Vaccines -->
  <h2>1. Licensed Vaccine Candidates for JEV</h2>
  <table>
    <thead>
      <tr>
        <th>Vaccine Name</th>
        <th>Type</th>
        <th>Status</th>
        <th>Key Features</th>
      </tr>
    </thead>
    <tbody>
      <tr>
        <td>IXIARO速 / JESPECT速 / JEEV速</td>
        <td>Inactivated (Vero cell)</td>
        <td>Licensed in U.S., EU, India, etc.</td>
        <td>Safe, effective, fewer side effects</td>
      </tr>
      <tr>
        <td>SA14-14-2</td>
        <td>Live attenuated</td>
        <td>Used in Asia (India, China, etc.)</td>
        <td>Single-dose, long-term immunity</td>
      </tr>
      <tr>
        <td>IMOJEV速</td>
        <td>Chimeric (Yellow Fever 17D vector)</td>
        <td>Licensed in Asia-Pacific</td>
        <td>Single dose, not for pregnancy</td>
      </tr>
      <tr>
        <td>JE-VAX</td>
        <td>Inactivated (mouse brain-derived)</td>
        <td>Discontinued in many countries</td>
        <td>Replaced due to safety concerns</td>
      </tr>
    </tbody>
  </table>

  <!-- Table 2: R&D Vaccines -->
  <h2>2. Research & Development Vaccine Candidates</h2>
  <table>
    <thead>
      <tr>
        <th>Vaccine Type</th>
        <th>Status</th>
        <th>Key Features</th>
      </tr>
    </thead>
    <tbody>
      <tr>
        <td>DNA Vaccines</td>
        <td>Pre-clinical / Early trials</td>
        <td>Stable, scalable, low immunogenicity</td>
      </tr>
      <tr>
        <td>mRNA Vaccines</td>
        <td>Experimental stage</td>
        <td>Inspired by COVID-19 success, rapid development</td>
      </tr>
      <tr>
        <td>Virus-Like Particle (VLP) Vaccines</td>
        <td>Pre-clinical</td>
        <td>Safe, strong immune response, no genome</td>
      </tr>
      <tr>
        <td>Plant-Based / Nanoparticle Vaccines</td>
        <td>Investigational</td>
        <td>Cost-effective, suitable for low-resource areas</td>
      </tr>
    </tbody>
  </table>

</body>
</html>
